US researchers have revealed(link is external) the identity of molecules on the surface of cancer cells which allow the body’s immune system to identify and destroy them.
The research could lead to a new generation of immunotherapies that are far more effective than those currently in use, that could target a range of cancers.
“This is a huge breakthrough,” said Cancer Research UK’s Dr Sergio Quezada, who works at UCL in London and was not involved in the research.
“The researchers were looking for ‘signatures’ on the surface of cancer cells associated with response to current immunotherapies, but their findings go further than that. They’ve actually discovered molecular motifs that will inform the development of the next generation of therapies,” he added.
The researchers, led by a team at the Memorial Sloan Kettering Cancer Centre in New York, analysed cancer DNA from 64 melanoma patients who had been treated with an immunotherapy drug called ipilimumab, half of whom had responded to the drug.
Ipilimumab works by switching on the body’s immune system to attack their cancer, but – for unknown reasons – it only works effectively in a minority of patients.
“We’ve been using a drug that empirically was found to be quite effective, and yet we didn’t have a detailed understanding of how it was working in people,” said Memorial Sloan Kettering’s Dr Jedd Wolchok.
Having analysed the patients’ cancer DNA, the researchers used sophisticated software to look for genetic mutations in the cancer cells that could predict whether patients had, or hadn’t, responded to the drug.
In doing so, they uncovered a series of genetic mutations in some of the patients that caused the cancer cells to produce short stretches of protein molecules, called peptide antigens, that make cancerous cells visible to immune response.
Tantalisingly, it appears that these mutations cause the antigens to mimic small parts of proteins produced by bacteria and viruses, explaining why they are so effective at triggering the immune response – although the researchers say more research will be needed to confirm this.
The discovery is “big, big news” for immunotherapy researchers says Cancer Research UK’s Dr Quezada. “This is the first time we’ve had an idea of what the immune system actually ‘sees’ on a tumour. Until now, it’s been hot topic of debate,” he said.
The Latest on: Immunotherapies
[google_news title=”” keyword=”Immunotherapies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Immunotherapies
- Brenus Pharma announces its international Scientific Committeeon June 7, 2023 at 9:00 am
This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid ...
- Untapping the full potential of immunotherapies for more people with canceron June 6, 2023 at 6:35 pm
Immunotherapy works by sparking the body’s own immune system into action against tumours. It has become a first-choice treatment for some types of cancer, and now there are exciting opportunities to ...
- Novocure's lung cancer device study raises concerns around commercial useon June 6, 2023 at 9:18 am
Novocure said on Tuesday its experimental device to treat a type of lung cancer showed a statistically significant improvement in extending overall survival among patients in a late-stage study.
- Head and neck cancer data presented at ASCO 2023on June 6, 2023 at 2:27 am
Results from two trials in the fight against head and neck cancer have been presented at the ASCO annual meeting in Chicago.
- Cellular Immunotherapy to Target NY-ESO-1 for Metastatic Melanoma by Avalia Immunotherapies for Metastatic Melanoma: Likelihood of Approvalon June 5, 2023 at 4:00 pm
Cellular Immunotherapy to Target NY-ESO-1 for Metastatic Melanomais under clinical development by Avalia Immunotherapies and currently in Phase II for Metastatic Melanoma.
- Gene engineered cell therapy developed to target brain metastatic melanomason June 5, 2023 at 3:47 pm
Overall survival for patients with melanoma that has spread to the brain is only four to six months. Immunotherapies, which harness the power of the immune system to attack cancer cells, have garnered ...
- Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinomaon June 5, 2023 at 3:06 pm
The final analysis of the JUPITER-02 clinical trial (NCT03581786) demonstrated a statistically significant and clinically meaningful improvement in OS for NPC patients who were treated with ...
- Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Developmenton June 5, 2023 at 2:03 pm
Janux Therapeutics, Inc. JANX (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T ...
- Global Allergy Immunotherapies Market Report 2023: Growing Consumer Awareness Towards Health Benefits Of Allergy Immunotherapies Fuels The Sectoron May 25, 2023 at 6:09 pm
The "allergy immunotherapies market: global market size, forecast, insights, and competitive landscape" report has been added to ResearchAndMarkets.com's offering. The global allergy immunotherapies ...
- Global Allergy Immunotherapies Market Report 2023: Growing Consumer Awareness Towards Health Benefits of Allergy Immunotherapies Fuels the Sectoron May 25, 2023 at 5:40 pm
DUBLIN, May 25, 2023 /PRNewswire/ -- The "Allergy Immunotherapies Market: Global Market Size, Forecast, Insights, and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.
via Bing News